Guardian Pharmacy Services, Inc. (NYSE:GRDN) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Guardian Pharmacy Services has a “Moderate Buy” consensus rating from nine analysts, with eight buys and one hold. The average 12-month price target is $43.83, implying potential upside from the stock’s $37.56 opening price.
• Recent analyst actions have generally been positive: Truist raised its target to $47, Oppenheimer increased its target to $49, and several firms upgraded their ratings, though Zacks downgraded the stock to hold.
• Guardian exceeded quarterly expectations, reporting $0.29 in earnings per share versus a $0.26 estimate and revenue of $351.77 million versus the $340.45 million consensus forecast.

Shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN - Get Free Report) have earned a consensus rating of "Moderate Buy" from the nine ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $43.8333.

Several equities research analysts have commented on the stock. Truist Financial boosted their target price on shares of Guardian Pharmacy Services from $43.00 to $47.00 and gave the stock a "buy" rating in a research report on Wednesday, June 17th. Wall Street Zen upgraded shares of Guardian Pharmacy Services from a "hold" rating to a "buy" rating in a research note on Sunday, August 9th. Oppenheimer upped their target price on shares of Guardian Pharmacy Services from $43.00 to $49.00 and gave the stock an "outperform" rating in a research report on Friday, August 7th. Zacks Research downgraded shares of Guardian Pharmacy Services from a "strong-buy" rating to a "hold" rating in a research report on Monday, May 11th. Finally, Weiss Ratings raised Guardian Pharmacy Services from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Thursday, August 20th.

Hedge Funds Weigh In On Guardian Pharmacy Services

Hedge funds and other institutional investors have recently bought and sold shares of the company. Ameritas Investment Partners Inc. raised its position in Guardian Pharmacy Services by 26.5% during the third quarter. Ameritas Investment Partners Inc. now owns 1,647 shares of the company's stock worth $43,000 after acquiring an additional 345 shares during the last quarter. California State Teachers Retirement System grew its position in shares of Guardian Pharmacy Services by 3.4% in the fourth quarter. California State Teachers Retirement System now owns 17,983 shares of the company's stock valued at $541,000 after purchasing an additional 593 shares during the last quarter. Police & Firemen s Retirement System of New Jersey grew its position in shares of Guardian Pharmacy Services by 20.4% in the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 6,070 shares of the company's stock valued at $183,000 after purchasing an additional 1,028 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Guardian Pharmacy Services by 13.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 11,885 shares of the company's stock worth $358,000 after purchasing an additional 1,409 shares in the last quarter. Finally, Clearstead Advisors LLC increased its stake in shares of Guardian Pharmacy Services by 196.3% during the 4th quarter. Clearstead Advisors LLC now owns 2,628 shares of the company's stock worth $79,000 after purchasing an additional 1,741 shares in the last quarter.

Guardian Pharmacy Services Trading Up 0.7%

Shares of GRDN stock opened at $37.56 on Thursday. The stock has a 50 day simple moving average of $40.10 and a 200-day simple moving average of $37.86. The company has a market cap of $1.87 billion, a price-to-earnings ratio of 36.47, a price-to-earnings-growth ratio of 1.93 and a beta of 0.10. Guardian Pharmacy Services has a 12-month low of $23.14 and a 12-month high of $47.02.

Guardian Pharmacy Services (NYSE:GRDN - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.29 earnings per share for the quarter, beating analysts' consensus estimates of $0.26 by $0.03. The firm had revenue of $351.77 million for the quarter, compared to the consensus estimate of $340.45 million. Guardian Pharmacy Services had a return on equity of 29.97% and a net margin of 4.50%. On average, equities analysts forecast that Guardian Pharmacy Services will post 1.19 earnings per share for the current fiscal year.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source